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ABSTRACT
Artemisinin-based Combination Therapy (ACT) to treat uncomplicated Plasmodium 
falciparum  malaria has been applied in Purworejo District, Central Java, Indonesia, since 
2004. However evaluation of the two ACT regimens used ie: Artesunate Amodiaquine 
(AAQ) and Dihydroartemisinin-Piperaquine (DHP) co-administered with Primaquine (PQ) 
has not been performed. This study aims to evaluate the efficacy and adverse events of 
AAQ+PQ and DHP+PQ treatment in uncomplicated falciparum malaria in Purworejo. In 
this descriptive and observational study, 46 Pf infected patients who fullfill the inclusion 
and exclusion criterias were recruited from December 2010 to August 2011. Standard 
ACT treatment were given to the patients followed by WHO drug efficacy evaluation for 
28 days. The clinical symptoms and adverse events was also evaluated over the course of 
the treatment. From all recruited subjects, 37 patients received DHP+PQ and 9 patients 
received AAQ+PQ. On the DHP+PQ treated patient, all subjects were free of asexual 
and sexual parasites by Day-3 while on AAQ+PQ treated patient, this parasite clearance 
was achieved faster as early as on D-2 at the latest. On the otherhand, the disappearance 
of fever was also last longer in DHP+PQ treated patient which in one patient last on 
D-14, while in AAQ+PQ treated patient, the symptom of fever dissappeared by D-2 
at the latest. No Early or Late Treatment Failures were found on either DHP+PQ or 
AAQ+PQ treatment as well as clinical and parasitological failures. However, the presence 
of adverse events cause by both drugs should not be ignored to ensure drug compliance.
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ABSTRAK
Terapi malaria dengan Artemisinin-based Combination Therapy (ACT) untuk malaria tanpa 
komplikasi diterapkan di Kabupaten Purworejo, Jawa, Indonesia, sejak tahun 2004. Namun 
demikian evaluasi terhadap efektivitas dua regimen ACT yang digunakan yaitu Artesunate 
Amodiakuin (AAQ) dan Dihydroartemisinin-Piperaquine (DHP) disertai Primakuin (PQ) 
belum pernah dilakukan. Penelitian ini bertujuan untuk mengevaluasi efikasi dan adverse 
events AAQ + PQ dan DHP + PQ pada penderita malaria tanpa komplikasi di Purworejo. 
Penelitian ini merupakan penelitian deskriptif dan observasional. Subjek penelitian adalah 
pasien yang terinfeksi P. falciparum yang memenuhi kriteria inklusi dan eksklusi,  direkrut 
dari Desember 2010 hingga Agustus 2011. Status resistensi obat, dan adverse events 
dievaluasi menggunakan cara evaluasi baku WHO selama 28 hari. Dari semua subjek 
yang direkrut (46), 37 penderita diobati dengan DHP + PQ dan 9 penderita dengan AAQ 
+ PQ. Pada kelompok yang mendapat pengobatan DHP + PQ, semua subyek bebas 
dari parasit stadium aseksual dan seksual pada hari ke 3, sedangkan kelompok yang 
mendapatkan pengobatan AAQ + PQ, parasit sudah menghilang dari sirkulasi darah pada 
hari-2. Semua penderita yang diobati DHP+PQ gejala demam menghilang lebih lama yaitu 
sampai hari ke 14, sedangkan pada penderita yang diobati dengan AAQ + PQ gejala 
demam sudah menghilang sejak hari ke 2. Tidak ada kegagalan pengobatan dini maupun 
kegagalan pengobatan lanjut baik secara klinis maupun parasitologi pada penggunaan 
kedua obat tersebut. Walaupun demikian, adverse events sebaiknya tidak diabaikan untuk 
memastikan kepatuhan obat.
Keywords : falciparum malaria – artesunate + amodiaquine – dihydroartemisinin + 
piperaquine - treatment failure - adverse events 
INTRODUCTION
Malaria remains a public health problem 
in more than 100 countries, including 
Indonesia. It is estimated that 300-500 million 
clinical cases occurs worldwide annually.1 
Among four species of Plasmodium that 
infect humans, P. falciparum is the most 
virulent species and cause high morbidity 
and mortality (1 million per year). Malaria 
incidence in Indonesia had been reported 
to decline in the last decade. Compared to 
2008, the Annual Parasite Incidence (API) 
in Indonesia in 2009 has decreased from 
3.82 to 1.85 per million population. Java and 
Bali were classified as low endemic areas. 
However, despite of a continuous control 
measures malaria outbreaks have occurred 
sporadically in Indonesia in 2009, including 
Java Island.2
Malaria control efforts in Indonesia have 
faced many constraints such as shortage of 
budgets, human resourse, insecticide-resistent 
vectors, ineffective intervention strategies and 
treatment failure due to parasite resistance to 
many antimalarial drugs.3 Parasite resistance 
is defined as the Plasmodium parasites ability 
to survive or proliferate within a theuraphetic 
or higher of the recommended dosage but 
still within patient tolerance.4 Based on the 
WHO and Indonesian Malaria Diagnosis 
Expert Committee (KOMLI), Artemisinin-
based combination therapy (ACTs) should be 
implemented in Indonesia in 2004. In Indonesia, 
there are currently two ACT regimens used 
in the malaria program i.e. artesunate-
amodiaquine (AAQ) and dihydroartemisinin-
piperaquine (DHP). Malaria parasite are 
known very adaptive and the reduction of 
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sensitivity to anti malaria drug is predicted to 
appear along with the widespread use of ACT.5 
The indication of the reduction of sensitivity 
of P. falciparum to AAQ/ DHP was reported 
by Hasugian et al.6 in Southern Papua, AAQ 
with treatment failure of 45% and treatment 
failure for DHP was 13%.. Similar studies on 
AAQ resistance were also reported in Gabon, 
Ghana, Madagaskar, Rwanda, Sierra Leone, 
Zanzibar and Myanmar with treatment failure 
ranged from 8.7% to 27%; and in Kenya the 
treatment failure of DHP was reported 8.3%. 4
Purworejo is a district in Central Java 
that was classified as low-endemic areas in 
Indonesia.7 Incidence of malaria in Purworejo 
is influenced by several factors. These 
include. high mobility of people to and from 
disease endemic areas, geography, behavior 
of the population and also the presence of 
efficient malaria vector mosquitoes.8 Malaria 
control efforts were emphasized in 2002 by 
Gebrak Malaria programme that includes the 
strengthened on surveillance, vector control, 
and treatment. The success of this program 
was demonstrated by the decrease in malaria 
cases from 2002 to 2004. However, malaria 
cases have been increasing afterwards  and 
outbreaks have been common in some 
villages9 starting in 2006.
Purworejo was confirmed as a region 
with  multidrug resistance parasite10,11 in 2003, 
and therefore the used of ACT (Artesunate-
Lumefantrine, Coartem) was recomended 
to overcome treatment failure.12 When this 
study started in 2010, ACT regimen used in 
Purworejo were AAQ and DHP regimens.9 
Evaluation of AAQ efficacy in Purworejo 
has been performed by Kusumaningsih.13 
However, the AAQ used was without 
primaquine (PQ) as recommended.14 The 
results found that the AAQ treatment failure 
was 12.9%, indicating reduced sensitivity 
to the AAQ that may cause malaria cases 
continue to appear.
Therefore, the objectives of this 
study were:  1. To evaluate the efficacy of 
AAQ+PQ and DHP+PQ on the treatment 
of uncomplicated falciparum malaria in 
Purworejo. 2. To evaluate possible adverse 
events on the used of AAQ+PQ and DHP+PQ 
on the treatment of uncomplicated falciparum 
malaria in Purworejo. The results will provide 
valuable information regarding the status of 
ACT regimens and the used of this drug as 
effective and safe regimen for the population 
of Purworejo. 
MATERIALS AND METHODS
This is an observational analytic study 
and was conducted in Purworejo District 
from December 2010 to August 2011. 
Subjects were patients with uncomplicated P. 
falciparum malaria who met the inclusion and 
exclusion criteria15. The study was conducted 
in coordination with District Health Office of 
Purworejo and local health workers of related 
Primary Health Centers in Purworejo. Subjects 
were malaria patients identified during passive 
or active case finding. Subjects were treated 
with DHP/Artekin® (Dihydroartemisinin 2-4 
mg/kg body weight (BW) and Piperaquine 
16-32 mg/kg BW); or with AAQ/Arsuamon® 
(Amodiaquine 10 mg/kg BW and artesunate 4 
mg/kg BW); co-administered with Primaquine 
(0.75mg/kg BW) on the first day as suggested 
by the Indonesian National Policy.14 The 
administration of AAQ or DHP depended 
on the availability of either AAQ or DHP 
in each Primary Health Center. Collection 
and examination of peripheral blood smear 
(both thin and thick) were conducted from 
Day 0 (D0) to D28 for patients being treated 
with AAQ and D0 to D42 for patients being 
treated with DHP. Stained blood films were 
examined by laboratory personnel of a related 
Primary Health Centers and cross checked 
by the Department of Parasitology, Faculty 
of Medicine, Universitas Gadjah Mada, 
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Yogyakarta. Patient complaints and clinical 
symptoms were documented and observed 
during follow up as well as during blood 
sample acquisition. Therapeutic responses 
assessed were Early Treatment Failure and 
Late Treatment Failure (Late Clinical Failure/
Late Parasitological Failure) as defind in 
WHO guidelines.15 Side effects or adverse 
event were defined as any clinical sign or 
symptom that did not exist during first visit 
(D0) but appeared after, or already existed and 
were aggravated during the follow up period.
This study was reviewed and approved 
by Institutional Review Boards for the ethical 
conduct of research on human subjects 
at the Faculty of Medicine, Universitas 
Gadjah Mada, Yogyakarta. Informed consent 
was collected from subjects before their 
participation in this study.
RESULTS
Of the 77 malaria patients recruited, 
only 46 were followed until day 28 for AAQ 
and day 42 for DHP.  The reasons for that is 
mostly related with geographical situation, 
a number of patient refused to be visited or 
migrated to other place of residency. Patients 
came from 14 villages spread over 7 sub-
Districts in Purworejo i.e. Kaligesing, Bener, 
Bagelen, Pituruh, Pecan, Loano, and Gebang 
sub-District. 
The characteristics of the subjects were 
shown in TABLE 1. The major complaints 
of subjects on the commencement of this 
study are shown in TABLE 2. Fever is the 
most common clinical manifestation among 
46 uncomplicated falciparum malaria patient 
in Purworejo (91.3%) follwed by dizziness, 
headache and muscle pain, however, 4 patient 
TABLE 1.  The characteristics of uncomplicated falciparum malaria patient in the Purworejo 
District included in the ACT efficacy study
Characteristics
                 Patient treatment regimen
AAQ (n=9) DHP(n=37) Total (n=46)
Age
•	 5-15 
•	 16-45
•	 ≥46
Sex
•	 Male
•	 Female
Plasmodium stage
•	 Trophozoit +gametes      
•	 Trophozoit
Parasite density
•	 1000-10,000
•	 >10.000-50,000
•	 >50,000-100,000
Axilla temperature (0C)
•	 ≥ 37.5
•	 < 37.5
2
4
3
7 
2 
3
6
7
2
0
8 
1
6 
18
13
18
19 
9
28
                 
22                         
12
3
                                                 
34 
3
  8
22
16
25
21
12
34
 
29
14
  3
 42
   4
n=number of samples; parasite density is the number of asexual parasite per µl blood
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(87%) did not experience any clinical sign 
(asymptomatic). Parasite density did not seem 
to correlate much with fever, 25 out of 29 (86%) 
patients with parasite density between 1000-
10.000 parasite/ul experiencing fever, as well 
TABLE 2.  Clinical symptoms of uncomplicated falciparum 
malaria patient in  Purworejo District involved in 
the ACT efficacy study conducted from December 
2010 to August 2011
Patients’ clinical 
symptoms
(N= 46) %
Fever
Dizziness
Headache
Shivering
Anorexia
Muscle pain
Coughing
Vomiting
91.30
91.30
89.13
71.74
63.04
78.26
4.35
15.22
TABLE 3.  The present or absent of fever in uncomplicated falciparum malaria patient in 
Purworejo District involved in the ACT efficacy study conducted from December 
2010 to August 2011 according to parasite density
  Parasite density
(no. of asexual/ul)
                      Symptom of fever
         Fever        No fever Total
1000-10,000
>10,000-50,000
>50,000-100,000
 25 (86%)
14 (100%)
3 (100%)
4 (14%)
0
0
29
14
  3
The percentage of patients that were free 
of fever following DHP+PQ treatment (n= 
37) was 41%, 76%, 89%, 97% on day 1, 2, 
3, 7 respectively. All patients were fever-
free on day 14. The percentage of patients 
who were free of asexual parasites was 76%, 
95.6% on day 1 and 2 and all patients (100%) 
were free of parasites on day 3 of follow-up 
(FIGURE 1). Different results were shown by 
subjects treated with AAQ+PQ (n = 9), i.e. the 
percentage of patients with free fever is 67% 
on day 1 and reached 100% on day 2, while 
the percentage of patients with free asexual 
parasites is 90% on the first day and reached 
100% on day 2 (FIGURE 2).
as all patients with higher parasite density (14 
and 3 patients with parasite density > 10,000-
50,000 and 750,000-100,000 respectively). 
(TABLE 3).
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FIGURE 1.  The disappearance of fever and asexual parasite in uncomplicated 
malaria patients following DHP+PQ treatment.
FIGURE 2.  The disappearance of fever and asexual parasites in uncomplicated 
falciparum malaria patients following treatment with AAQ+PQ.
On the first day patients were recruited 
in the study, 25% and 35% subjects carried 
gametocytes before the administration of 
DHP and AAQ respectively. On treatment 
with DHP+PQ, number of gametocytes-
carrier patients reduced from 24.32% on day 0 
to 21.62% and 10.81% on day 1 and 2 follow-
up, and reached 0% (cleared-up) by the third 
day follow-up. On treatment with AAQ+PQ, 
number of gametocytes carrier patients 
reduced from 33% on day 0 to 22% both on 
day 1 and 2 follow-ups respectively, and 0% 
(cleared-up) on the third day post treatment 
(FIGURE 3).
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FIGURE 3.  The disappearance of gametocyte in P. falciparum-infected sub-
jects  treated with AAQ+PQ or DHP+PQ during follow up.
As shown on FIGURE 4, the clinical 
symptom of malaria dissapeared following 
ACT treatment. In group treated with 
DHP+PQ, the percentage of subjects have no 
clinical symptoms was 5%, 25%, 70%, 80%, 
and 90% on day 2, 3, 7, 14 and 21 follow-up. In 
group treated with AAQ+PQ, all subject still 
have clinical symptoms until day 3 follow-
up, and afterwards, the percentage of subjects 
with clinical symptoms began to decrease on 
day 7 and 14,  to 40%, and 70% respectively 
(FIGURE 5). All subjects were free of clinical 
symptoms on day 28 for DHP and on day 21 
for AAQ treatment. The dominant clinical 
signs were headache, dizziness and muscle 
pain for subjects treated with DHP+PQ and 
headache, dizziness and loss of appetite for 
subjects treated with AAQ. Both regiments 
showed neither early or late treatment failure 
(TABLE 4).
FIGURE 4.  The disappearance of clinical symptoms in uncomplicated falci-
parum malaria patients treated with DHP + PQ during follow up.
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FIGURE 5.  The disappearance of clinical symptoms in uncomplicated falciparum 
malaria  patients treated with AAQ+PQ during follow up.
TABLE 4.  The result of the evaluation of ACT treatment to uncomplicated falciparum malaria 
patient in the Purworejo District from December 2010 to August 2011.
Drugs
Status of Resistance (%)
Total
Sensitive Early RI Late RI R II R III
DHP+PQ 100 0 0 0 0 100 
AAQ+PQ 100 0 0 0 0 100 
Total 100 0 0 0 0 100 
On treatment with DHP+PQ, side effects 
disappeared by D-1 in 5% subjects. This 
percentage increased to 25% on D-3, and to 
75% on D-7. All subjects were free of side 
effects on D-28 (FIGURE 6). The dominant 
side effects with DHP+PQ treatment were 
nausea, stomach pain and dark urine. A small 
proportion of subjects (3%) complained 
of discomfort while breathing after the 
administration of DHP+PQ. All subjects 
complained of having adverse events with 
AAQ+PQ from D1 to D3. On D-7, +50% 
subjects were free of adverse events and 
this percentage increased on D-14 (80%) 
and all subjects (100%) were free of adverse 
events on D-21 (FIGURE 6). The dominant 
adverse events in order of occurrence were 
nausea, dark urine, stomach pain, vomit, and 
discomfort while breathing.
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FIGURE 6. Adverse events seens in patients treated with DHP+PQ during follow up
FIGURE 7. Side effects seens in patients treated with AAQ + PQ during follow up  
DISCUSSION
From 46 subjects observed in this study, 
48% were in productive age (16-45 years 
old). These probably related with the chance 
of getting the infection since people in this 
group of age are more active compared to 
childhood and elderly. The majority of malaria 
patient in Purworejo were symptomatic with 
predominat symptom of fever, diziness and 
muscle pain and only less than ten percent 
were asymptomatic. These clinical picture 
are representing characteristic of malaria 
patient from low endemic areas where the 
transmission are low and may be seasonal 
which do not stimulate effective immune 
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responses and therefore symptomatic malaria 
patients must be common in this such low 
endemic areas. These condition are also in 
accordance with the low seroprevalence and 
antibody levels of population in Purworejo.16 
Asymptomatic patient were expectedly be 
found in area of higher endemicity such as 
in Lampung17, where higher level of malaria 
transmission will stimulate higher antibody 
responses, resulting in higher seroprevalence 
and higher antibody level in the serum16 that 
might suppressed the clinical manifestation of 
the diseases. 
The presence of subject with gametocytes 
(26%) on day 0 probably suggesting that 
transmission might be still in progress during 
the study since Purworejo was a receptive 
areas where Anopheles mosquito vector are 
always available in most of the time8, readily 
transmits any gametocytes within the blood 
circulation of the nearby population. The 
factor that might stimulate the differenciation 
to gametocytes might varies such as the 
host immune responses, oxidative stress or 
other condition that make the parasite in 
uncomfortable condition.18 The presence of 
gametocyte in the blood circulation of malaria 
patient must be take as highly priority of 
attention since it is critical for transmission to 
other people. Anti gametocytocidal drug must 
be given and prevention to mosquito bite are 
also very essential. 
In this study both DHP+PQ and AAQ+PQ 
treatment resulted in the rapid clearance of 
both asexual and sexual form of the parasite 
by day 3 of the follow-up. ACT is known 
as a potent blood schizonticides which also 
have an anti gametocidal effect but only 
against immature gametocytes, and therefore 
addition of Primaquine on the first day of 
ACT treatment are still essential to kill the 
mature gametocytes.19 Efficacy study of DHP 
treatment without PQ had been  carried-out 
in Kalimantan and Sulawesi by Siswantoro 
et al.20 and reported that in those study 
gametocytes were still detected on D-28 of 
the follow-up. The similar result was shown 
when using Artemisinin-mefloquine without 
PQ in Thailand.21 The effect of primaquine 
on the treatment of malaria using ACT was 
also shown in Lampung by Inge et al.22 
and the result indicated that the addition 
of primaquin may fastened the gametocyte 
clearance from the blood circulation as 
compared to ACT whithout prmaquine. The 
efficacy of DHP+PQ and AAQ+PQ on the 
treatment of uncomplicated malaria patient 
in the Purworejo District indicated that these 
regiment are still sentitive, no early nor late 
treatment failure. Although the efficacy 
of DHP+PQ and AAQ+PQ in this study 
seems still promising, further study that 
includes more subject at least 50 subjects as 
recommended by WHO are highly suggested 
to make statistically significant conclusion. 
Despite the effectiveness of DHP+PQ 
and AAQ+PQ in the clearance of sexual and 
asexual parasites, this study also showed that 
both regiments also rapidly reduce most of 
the clinical symptoms appeared on the patient 
with more intensive in DHP+PQ as compared 
to AAQ+PQ, except for fever which was 
last longer until day 14 in DHP+PQ treated 
patients. Shiver was also common symptom 
appeared in malaria patient in Purworejo, 
however, this symptom rapidly dissappeared 
on the following day of the first ACT treatment. 
Although both treatments  also causing some 
adverse events, i.e. symptoms that initially 
absent but appeared following treatment or 
initially present and than agravated following 
treatment. The major adverse events arosed 
were nausea, stomach pain and dark urine. 
These adverse events were less and minimal 
in DHP treated patients. Furthemore, they 
also dissapear faster in DHP treated patients. 
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Similar adverse events during the used 
of DHP was also repoted by Hasugian et 
al.6 during treatment against multidrugs-
resistant malaria in Papua suah as nausea, 
vomiting, and anorexia. These adverse events 
diminished on D-7, and were also milder and 
better tolerated than those treated with AAQ. 
Vomiting, stomach pain and discomfort during 
breathing/dyspnea was also been reported with 
DHP treatment23, 24  but there was no evidence 
of the ECG changes.23 Adverse events 
seen during and after treatment needs to be 
considered as an important factor that might 
contribute to patient compliance for malaria 
drugs regimens.25 The fact that some subjects 
complained dark urine during treatment or 
follow-up days suggested that some subjects 
might experienced hemolysis as a results of 
enzyme disorder condition (G6PD). 
CONCLUSION 
Treatment of uncomplicated falciparum 
malaria patients using DHP+PQ and AAQ+PQ 
is successful in clearing of the asexual parasites 
in the Purworejo District with no Early nor 
Late Treatment Failure, and therefore no 
artemisinin resistance is observed. The co-
administration of primaquine onto these 
regiments is useful in gametocyte clearance 
adding the benefit of  possibly blocking 
the transmission. It is recommended that 
DHP+PQ or AAQ+PQ should still be used in 
the Purworejo District realizing that adverse 
events may be an issue with compliance. Dark 
urine that found in some subjects demands 
further study on the prevalence of G6PD 
deficient in this region.
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